

The widening scope of cellular therapy

Preceding the
33rd Annual Meeting of the
European Group for Blood
and Marrow Transplantation
11:00–13:00 h

Cité Centre de Congrès Lyon, France
Forum 1

The widening scope of cellular therapy

Chairman:

Norbert-Claude Gorin, MD, Paris, France

Sunday, March 25, 2007

11:00–13:00 h

Cité Centre de Congrès Lyon, France

Forum 1

Preceding the 33rd Annual Meeting
of the European Group for Blood
and Marrow Transplantation

This symposium is supported
by an unrestricted educational
grant from Miltenyi Biotec



AGENDA

- 11:00 Introduction**
Norbert-Claude Gorin, Paris, France
- 11:05 Haploidentical transplantation using post-transplant T cell immunotherapy to reconstitute anti-viral immunity**
Helen Heslop, Houston, USA
- 11:25 Haploidentical transplantation in adults with CD3/CD19 depleted grafts and reduced-intensity conditioning**
Christoph Faul, Tübingen, Germany
- 11:45 Clinical-scale combined CD4 and CD8 depletion for infusion of donor innate lymphocyte infusions (DILI)**
Volker Kunzmann, Würzburg, Germany
- 12:05 Intramyocardial stem cell transplantation for chronic ischemic heart failure—phase II results and the Berlin Cardio 133 trial**
Christof Stamm, Berlin, Germany
- 12:25 CD34⁺ selected stem cell boosts for treatment of patients with poor graft function**
Andrea Bacigalupo, Genova, Italy
- 12:45 Discussion**

PROGRAM FACULTY

- CHAIR Norbert-Claude Gorin, MD**
Head of the Department of Hematology and Cell Therapy,
Hôpital Saint-Antoine, Paris, France
- FACULTY Helen Heslop, MD**
Director, Baylor College of Medicine, The Methodist Hospital and Texas
Children's Hospital, Center for Cell & Gene Therapy, Houston, USA
- Christoph Faul, MD**
Senior Physician and Head of the Blood and Marrow Transplant Program,
Medical University Hospital, Department of Oncology, Hematology,
Immunology, Rheumatology and Pulmology, Tübingen, Germany
- Volker Kunzmann, MD**
Senior Physician, Head of the Laboratory for Graft Engineering and
Immunophenotyping, Medical Clinic and Policlinic II,
Julius-Maximilians University of Würzburg, Würzburg, Germany
- Christof Stamm, MD**
Staff Surgeon, German Heart Institute Berlin, Berlin, Germany
- Andrea Bacigalupo, MD**
Head of the Department of Hematology, Ospedale San Martino, Genova, Italy

The CliniMACS® System components (Reagents, Tubing Sets, Instruments and PBS/EDTA Buffer) are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked devices.

In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS® MicroBeads are for research use only and not for use in humans.

CliniMACS is a registered trademark of Miltenyi Biotec GmbH.